Abstract：【Objective】To investigate the efficacy of anlotinib combined with programmed death-1(PD-1) inhibitor in the treatment of patients with advanced non-small cell lung cancer(NSCLC). 【Methods】A retrospective analysis was conducted on the clinical data of 90 NSCLC patients, who were divided into the control group(n=30, treated with anlotinib) and the observation group(n=60, treated with anlotinib combined with PD-1 inhibitor) based on different treatment methods. The short-term efficacy, survival, and drug safety of the two groups were compared. 【Results】After treatment, the objective response rate(ORR) in the observation group was 11.67%(7/60), and the disease control rate(DCR) was 60.00%(36/60), which were higher than those in the control group [ORR: 6.67%(2/30), DCR: 33.33%(10/30)], with statistically significant differences(P<0.05). The median progression-free survival(PFS) in the observation group was 10 months, and the median overall survival(OS) was 13 months. Both PFS and OS in the observation group were longer than those in the control group(median PFS: 7 months, median OS: 11 months), with statistically significant differences(P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05). 【Conclusion】The combination of anlotinib and PD-1 inhibitors in the treatment of advanced NSCLC can effectively improve the short-term efficacy and extend the survival time of patients.
王惠, 贾靖, 王辉. 安罗替尼联合程序性死亡蛋白-l抑制剂治疗晚期非小细胞肺癌患者的临床疗效[J]. 医学临床研究, 2024, 41(6): 810-812.
WANG Hui, JIA Jing, WANG Hui. Clinical Efficacy of Anlotinib Combined with PD-1 Inhibitor in the Treatment of Advanced Non-Small Cell Lung Cancer. JOURNAL OF CLINICAL RESEARCH, 2024, 41(6): 810-812.
2024, Vol. 41 
